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Abstract
Purpose In patients with ipsilateral breast tumor recurrence (IBTR), the detection of distant disease determines whether the 
intention of the treatment is curative or palliative. Therefore, adequate preoperative staging is imperative for optimal treatment 
planning. The aim of this study is to evaluate the impact of conventional imaging techniques, including chest X-ray and/or 
CT thorax-(abdomen), liver ultrasonography(US), and skeletal scintigraphy, on the distant recurrence-free interval (DRFI) 
in patients with IBTR, and to compare conventional imaging with 18F-FDG PET-CT or no imaging at all.
Methods This study was exclusively based on the information available at time of diagnoses of IBTR. To adjust for dif-
ferences in baseline characteristics between the three imaging groups, a propensity score (PS) weighted method was used.
Results Of the 495 patients included in the study, 229 (46.3%) were staged with conventional imaging, 89 patients (19.8%) 
were staged with 18F-FDG PET-CT, and in 168 of the patients (33.9%) no imaging was used (N = 168). After a follow-up of 
approximately 5 years, 14.5% of all patients developed a distant recurrence as first event after IBTR. After adjusting for the 
PS weights, the Cox regression analyses showed that the different staging methods had no significant impact on the DRFI.
Conclusions This study showed a wide variation in the use of imaging modalities for staging IBTR patients in the Nether-
lands. After using PS weighting, no statistically significant impact of the different imaging modalities on DRFI was shown. 
Based on these results, it is not possible to recommend staging for distant metastases using 18F-FDG PET-CT over conven-
tional imaging techniques.
Keywords Breast cancer · Ipsilateral breast tumor recurrence · Preoperative screening · Conventional imaging · 18F-FDG 
PET-CT · Distant metastasis · Propensity score weight
Introduction
In patients with ipsilateral breast tumor recurrence (IBTR), 
adequate preoperative staging is imperative for tailoring 
optimal treatment plans. The absence or presence, and if 
so, the extensiveness of distant metastases determines the 
curative or palliative intent of the treatment of patients with 
IBTR [1]. To evaluate for distant metastases at the time of 
IBTR, preoperative staging is recommended [2–4]. Con-
ventional imaging, including chest X-ray and/or CT thorax-
(abdomen), ultrasonography (US) of the liver, and skeletal 
scintigraphy, is the standard of care in many hospitals [2–4].
Besides these conventional imaging techniques, studies 
have focused on the value of 18-Flurorine-2-Fluoro-2-deoxy-
D-Glucose positron emission tomography (18F-FDG PET) 
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and 18F-FDG PET computer tomography (18F-FDG PET-
CT) in patients with cancer [5–8]. The combined 18F-FDG 
PET and CT technique provides anatomical and functional 
information, and has been demonstrated to be an accurate 
technique in staging patients with IBTR and for the detec-
tion of distant metastases [4, 9–12]. In a systematic review, 
Pennant et al. reported a sensitivity of 96% and specificity 
of 89% for 18F-FDG PET-CT [7]. Furthermore, 18F-FDG 
PET-CT is able to screen the whole body, including regional 
lymph nodes, in one session and may reduce the need for 
additional diagnostic procedures often needed to further 
analyze lesions found on conventional staging images [13].
However, 18F-FDG PET-CT is an expensive procedure 
and false-positive outcomes, caused for example by inflam-
matory processes, physiological muscle uptake, or old frac-
ture sites, could result in unnecessary additional procedures 
as well [7]. False-negative results can occur due to low FDG 
uptake in some conditions, such as invasive lobular carci-
noma, ongoing endocrine therapy, and small highly scle-
rotic skeletal lesions with low rate of actively replicating 
cells [14]. The clinical role of 18F-FDG PET-CT remains 
controversial [15], since there is no evidence of the impact 
of 18F-FDG PET-CT on patients’ outcomes. Guidelines are 
still quite conservative in recommending the use of 18F-FDG 
PET-CT as first tool for screening distant metastases, in both 
the primary and recurrent setting.
Theoretically, one could expect that patients screened 
with a more sensitive screening technique, such as 18F-FDG 
PET-CT [7], would experience less distant recurrences dur-
ing follow-up or would experience these later during follow-
up compared to patients screened with conventional imaging 
or no staging at all. Besides, with a more sensitive screening 
technique less patients would receive unnecessary curative 
treatments associated with high morbidity. Therefore, the 
aim of this study is to evaluate the impact of conventional 
imaging versus 18F-FDG PET-CT versus no imaging, on 
distant recurrence-free interval in patients diagnosed with 
IBTR, in order to optimize treatment planning.
Patients and methods
SNARB‑study design
The Sentinel Node and Recurrent Breast cancer (SNARB) 
study is a multicenter national registration study in which 
36 Dutch hospitals participated [16, 17]. Patients with 
clinically apparent ipsilateral or contralateral lymph node 
metastases and patients with distant metastases at the 
time of diagnosis of IBTR were excluded. A total of 536 
patients with IBTR were included in the SNARB study. No 
obligatory requirements were formulated in the protocol 
regarding the use of imaging modalities to stage patients 
diagnosed with an IBTR.
Patients
All patients with IBTR, treated with a curative intent, 
and staged cTxN0M0 were considered eligible for inclu-
sion. All included patients were divided into three groups 
according to the preoperative staging procedure: conven-
tional imaging, 18F-FDG PET-CT, or no staging at all. 
Conventional imaging included the use of the following 
imaging techniques: (1) chest X-ray and/or CT thorax-
(abdomen), (2) ultrasonography (US) of the liver or CT 
thorax-(abdomen), and (3) skeletal scintigraphy. Patients 
in the conventional imaging group who did not undergo 
a scan of the thorax, liver, and skeletal scintigraphy were 
excluded.
Definition of recurrences
Distant recurrences (DR) were defined as any evidence of 
disease outside the ipsilateral breast, contralateral breast, 
and regional lymph nodes. A regional recurrence (RR) 
was defined as any evidence of disease found in ipsilateral 
intramammary nodes, ipsi- and contralateral internal mam-
mary nodes, ipsi- and contralateral axillary nodes, and ipsi- 
and contralateral infra- and supra-clavicular nodes [18, 19]. 
Lymph node recurrences found outside these nodal basins 
were defined as distant metastatic disease. An event in the 
contralateral breast was defined as a new primary tumor and 
was not considered a recurrence, unless it could be proven 
that it was metastatic disease [20].
Follow‑up
In 2017, follow-up of the 536 patients in the SNARB study 
was updated. General practitioners were actively contacted 
for additional follow-up information when hospital records 
showed no outpatient clinic visits for more than 1 year. Date 
of last follow-up was documented as last visit to the outpa-
tient clinic, date of last visit to the general practitioner, or 
date of death in case the patient had deceased. Follow-up 
time was defined as the time between date of surgery for 
IBTR and date of last follow-up.
Distant recurrence-free interval (DRFI) was defined as 
the time between date of IBTR surgery and date of diag-
nosis of a DR or date of last follow-up. Only distant recur-
rences developing as first event after IBTR were recorded as 
a distant event. Distant recurrences occurring after a local 
or regional re-recurrence following IBTR were censored.
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Statistics
Only the information available at time of diagnosis of IBTR, 
so before systemic staging imaging, was used for the analy-
ses. The baseline characteristics were compared between the 
three staging groups. Categorical variables were tested with a 
Chi-square statistics or Fisher exact test when necessary and 
continuous variables were tested with a one-way ANOVA 
analysis. A 2-sided p value of < 0.05 was considered statisti-
cally significant.
The effect of the method of staging on the DRFI was ana-
lyzed with the use of propensity score (PS) adjustment. A PS 
was calculated for every patient, based on the possible con-
founders. Because the outcome of interest was divided in three 
staging methods groups, multinomial propensity scores were 
used. The propensity scores were calculated with the MNPS 
package, an extended version of the TWANG package, in R. 
To obtain the propensity score weights for multiple staging 
methods, a generalized boosted model (GBM) regression 
was used. The GBM was used with 3000 number of trees and 
different stopping rules were checked: the mean effect size, 
maximal effect size, mean Kolmogorov–Smirnov, and maxi-
mal Kolmogorov–Smirnov. For the specific research question, 
the average treatment estimation (ATE) comparison was used.
By using the GBM model, the overlaps between the three 
groups were checked. In practice, overlapping meant that every 
patient could have received each staging modality and that no 
values of the covariates occurred only in one of the staging 
groups. Box plots were used for comparing the distribution 
of propensity scores and testing the overlap. Generally, stand-
ardized mean differences of less than 0.20 were considered 
small (which is good), 0.40 were considered moderate, and 
0.60 were considered large.
Next to the overlap, also the balance of the three groups 
was assessed. Finally, a combination of the overlap plot, the 
balance plots, and covariate table were used to assess whether 
the groups were sufficiently similar to support causal estima-
tion of the primary research question.
After the propensity score weights were calculated, the 
weights were used in a weighted survival analysis to calculate 
the effect of the staging method on the DRFI. The effect was 
investigated with the use of Kaplan–Meier curves and tested 
with a Cox regression model. When a covariate was still unbal-
anced after PS weighting, the covariate was included in the 
Cox regression model to correct for it [21–23].
Results
Patients
Of the 536 patients for whom follow-up data were collected, 
21 (4%) were lost to follow-up due to emigration, lack of 
information, or withdrawal of informed consent. Of the 
515 (96%) remaining patients, 20 patients were only partly 
screened for distant metastases and therefore excluded, 
resulting in a study cohort of 495 patients (92.4%).
The median age at the time of IBTR was 64.0 years (range 
26–93). The median time from primary surgery to diagnosis 
of IBTR (DFI) was 10.6 years (range 0.4–32). The major-
ity of the patients had a primary tumor ≤ 2 cm (55.4%), a 
primary negative nodal status (72.1%, as determined by 
sentinel lymph node biopsy and/or axillary lymph node dis-
section), and hormone receptor-positive, human epidermal 
growth receptor 2 (HER2)-negative (67.9%). The differ-
ent covariates were divided per staging group are shown 
in Table 1, with the corresponding p values (unadjusted p 
value). In Table 1, it is shown that all variables are statisti-
cally significant, except for the median time from primary 
surgery to IBTR diagnose. In the 18F-FDG PET-CT group, 
more patients were primary treated with a mastectomy, and 
more patients had primary positive lymph nodes. In the no-
staged group, the patients had a higher mean age at time of 
IBTR (66 years vs. 63 years in the conventional group and 
62.5 years in the 18F-FDG PET-CT group). Those patients 
who received no staging were treated with adjuvant systemic 
therapy in only 60.7% of the cases, compared to 73.4% in 
patients who were staged. There was no difference in the 
administration of adjuvant systemic therapy between the 
conventional imaging staged group and 18F-FDG PET-CT, 
74.2% vs 71.4%, respectively (P = 0.588).
Preoperative staging modalities
Of the 495 patients, 229 patients (46.3%) underwent pre-
operative staging with conventional imaging, 89 patients 
(19.8%) with 18F-FDG PET-CT, and 168 (33.9%) received 
no preoperative staging imaging (N = 168) (Table 1). As 
shown in Fig. 1, the use of the different imaging procedures 
changed over time; the use of 18F-FDG PET-CT increased 
from 6.5% in 2008–2010 to 25.2% in 2013–2014, while the 
use of conventional imaging decreased from 58.1 to 31.7%. 
In 2008–2010, 33.1% of patients received no preoperative 
staging imaging, and this percentage fluctuated to 29.8% in 
2010–2011, 29.8% in 2011–2013, and 43.1% in 2013–2014.
Regional recurrences
Regional recurrences as first event after IBTR occurred in 
16 patients after a median time of 2.2 years (range 0.4–7.0). 
In eight patients, the regional recurrence was located in 
the contralateral axilla (N = 8). The other recurrences were 
located in the ipsilateral supraclavicular nodal area (N = 2), 
ipsilateral axillary (N = 1), parasternal (N = 2) or contralat-
eral infraclavicular nodal area (N = 1), or in multiple regional 
nodal areas (N = 2). The 6-year regional recurrence-free 
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interval was 96.1% (CI 94.1%–98.1%). Patients screened 
with conventional imaging had a 6-year RR of 96.4% vs. 
96.2% and 95.3% for patients with no imaging and 18F-FDG 
PET-CT (p = 0.766).
Distant recurrences
After a median follow-up period of 4.9  years (range 
0.3–13.2) after IBTR, 82 (16.5%) patients had experienced 
a distant recurrence, and in 10 (12.2%) of these patients a 
distant recurrence was diagnosed after a local re-recurrence 
(N = 4) or after a regional re-recurrence (N = 6). Predominant 
metastatic sites were the bones (30.6%; N = 22), the lungs 
(18.1%; N = 13), the liver (12.5%; N = 9), the brain (8.3%; 
N = 6), or to other places (12.5%; N = 9). In 13 patients, 
distant recurrences were found in multiple organs (18.1%; 
N = 13). Distant recurrence as first event occurred after a 
median time of 2.7 years (range 0.04–8.7) following treat-
ment of IBTR. The mean time of developing a distant recur-
rence after IBTR did not significantly differ between patients 
screened with 18F-FDG PET-CT, conventional imaging, or 
no imaging (p = 0.648).
Propensity score weighting, check PS weights, 
overlapping, and balance
The GBM was used and the convergence was achieved in 
all comparisons (Supplemental material, Fig. 3a, b, c). The 
overlap between the groups is shown in Table 1, but also in 
the box plots shown in Figs. 4a, b, c (Supplemental mate-
rial) and was good to moderate. Next to the overlap, the 
balance was also checked and is shown in Fig. 5 (Supple-
mental material). The balance looks sufficient; however, the IB
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18F-FDG PET-
CT imaging versus conventional imaging versus no imaging over 
time. 18F-FDG PET-CT 18-Flurorine-2-Fluoro-2-deoxy-D-Glucose 
positron emission tomography-computer tomography. The group 
of 0−124 were the first 124 patient treated for IBTR in 2002−2010, 
second group of 124 patients: 124−248 treated in 2010−2011, third 
group: 248−372 treated in 2011−2013, and 372−495 the last group 
of patients treated in 2013−2014
424 Breast Cancer Research and Treatment (2019) 175:419–428
1 3
covariate primary surgery (breast-conserving therapy versus 
mastectomy) was still not balanced correctly after propensity 
score weighting.
Baseline characteristics after PS weights
In Table 1, the adjusted p values, after adjusting the PS 
weights to the sample, are shown. After adjusting the PS 
weights, all the covariates, except for the covariate primary 
surgery, are no longer statistically significant and therefore 
balanced between the staging groups. Only the variable ‘pri-
mary surgery’ is taken as a covariate next to the PS weights 
in the cox regression model.
Survival curves of DRFI
Figure 2 presents the Kaplan Meier curves for the three dif-
ferent staging modalities (without correcting for the unbal-
anced covariate ‘primary surgery’) and showed no impact 
of the different imaging groups on the DRFI. Finally, Cox 
regression analyses were performed with and without the 
unbalanced covariate ‘primary surgery.’ The different 
staging modalities had no significant effect on the DRFI 
with a HR 0.86 (95% CI 0.37–1.98) for 18F-FDG PET-CT 
compared to no imaging and HR 0.96 (95% CI 0.55–1.67) 
for conventional imaging compared to no imaging (Table 2). 
By adding the covariate primary surgery to the Cox regres-
sion model (because of the imbalance after weighting), the 
effect of the different imaging groups remained (Table 2); 
however, the proportional hazard (PH) assumption became 
questionable. To assure the PH assumptions that were made, 
sensitivity analyses were performed for the primary breast-
conserving surgery group and showed no significant effect 
of the different staging modalities on the DRFI.
Discussion
In this nationwide cohort of 495 patients included in the 
SNARB study with an ipsilateral breast tumor recurrence, 
46.3% were preoperatively staged with conventional imag-
ing, 19.8% with 18F-FDG PET-CT, and 33.9% received no 
preoperative imaging at all to detect distant metastases. Dis-
tant recurrences, as a first event after treatment of IBTR, 
Fig. 2  Propensity score 
weighted Kaplan–Meier curves 
of distant recurrence-free 
interval according to stag-
ing method groups. 18F-FDG 
PET-CT 18-Flurorine-2-Fluoro-
2-deoxy-D-Glucose positron 
emission tomography-computer 
tomography
Table 2  Cox regression 
analyses for distant recurrence-
free interval
18 F-FDG PET-CT 18-Flurorine-2-Fluoro-2-deoxy-d-Glucose positron emission tomography-computer 
tomography
Coefficients Standard error p value Hazard ratio (95% 
confidence interval)
Without covariate
 None Ref
 18F-FDG PET-CT − 0.15425 0.42637 0.718 0.8571 (0.3716–1.977)
 Conventional − 0.04582 0.28627 0.873 0.9552 (0.5450–1.674)
With covariate
 None Ref
 18F-FDG PET-CT − 0.2523 0.4568 0.581 0.7770 (0.3147–1.902)
 Conventional − 0.1398 0.3122 0.654 0.8695 (0.4716–1.603)
 Primary surgery − 0.6393 0.4219 0.130 0.5277 (0.2308–1.206)
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occurred in 72 patients (14.5%). Propensity score analyses 
showed no difference in the likelihood of developing distant 
recurrence, according to the imaging strategy used at time 
of IBTR.
At baseline, all the covariates differed significantly 
between the three staging groups, except for the median 
time from primary surgery to IBTR diagnosis. To correct 
for these baseline differences, a PS analyses was used, with 
the aim to reduce or even eliminate confounding. PS meth-
ods are particularly appealing when multiple covariables are 
studied, and the number of events is rare [24, 25]. After 
propensity score analyses, we did not find a statistically sig-
nificant difference in the risk of distant metastases between 
the three staging groups. This finding is in accordance with 
the results of a study by Neuman et al., who reported no dif-
ference in the risk of developing distant recurrence between 
patients with imaging versus without imaging at the time of 
locoregional recurrence [26].
Historically, IBTR has been considered a risk factor for 
distant recurrence and thus resulting in a poorer progno-
sis [26–28]. Synchronous distant metastases are reported 
in up to 15–30% of patients with an IBTR and up to 35% of 
patients with isolated lymph node recurrence [26]. Factors 
found to be associated with the presence of synchronous 
metastases are the TNM stage of the primary tumor, with 
patients with more advanced stages having a higher risk 
[29], and the type of locoregional recurrence, with patients 
with lymph node recurrences having a higher risk compared 
to patients with IBTR [26]. Because of this high risk of syn-
chronous distant metastases, the recommendation is to stage 
all patients diagnosed with an IBTR for distant metastases.
In the current study, we did not observe a difference in the 
meantime to detection of distant recurrence, nor in the risk 
of regional recurrences after IBTR, between the different 
imaging strategies. Although current guidelines recommend 
the use of chest X-ray, liver ultrasonography or CT, and bone 
scintigraphy, these imaging modalities have been shown to 
be less sensitive and specific than 18F-FDG PET-CT [13]. 
Theoretically, occult metastases could be present at time of 
diagnosis of IBTR, though too small for detection on con-
ventional imaging modalities. Staging using a more sensi-
tive staging strategy, i.e., 18F-FDG PET-CT could prevent 
false-negative outcomes, by detecting the smaller distant 
metastasis. Synchronous small metastases missed at time of 
IBT could continue to grow, and could become clinical overt 
during follow-up. Thereby, 18F-FDG PET-CT is deemed to 
be especially valuable in the detection of extra-axillary nodal 
metastases [13, 30]. In the current study, the lack of differ-
ence in time to detection of distant recurrence and in the 
regional recurrence risk does not support these hypotheses.
Imperative for patients is the impact of distant staging 
on patients’ treatment plan. Changes in treatment plans 
could include initiation or avoidance of medical treatment 
such as hormone therapy and chemotherapy, but also surgi-
cal treatment of IBTR [7]. If extensive metastatic disease 
is diagnosed, patients are generally considered not curable 
and treatment is aimed to alleviate symptoms and, if possi-
ble, prolong survival [5, 7]. Omitting local treatment spares 
patients the morbidity associated with surgery and/or radio-
therapy and minimizes the impact of these treatments on 
quality of life. Therefore, no staging at time of IBTR may 
lead to unnecessary exposure to potentially harmful local 
surgical procedures [31]. Furthermore, guidelines recom-
mend treating patients with IBTR, especially those with 
estrogen receptor-negative tumors, with adjuvant chemother-
apy, while in the case of synchronous metastasis the standard 
treatment with adjuvant chemotherapy will be postponed 
until having symptomatic metastasis. Neuman et al. found 
that 27% of 445 patients with a locoregional recurrence had 
synchronous distant metastases at time of their IBTR [26]. 
Hypothetically, choosing not to stage patients with IBTR 
will lead to overtreatment of up to those 27% of patients. 
The impact on patient management and patient’s physical 
as well as mental status underscores the need for accurate 
staging modalities in this group of IBTR patients who have 
a variety of treatment options available to them.
Over time, many studies presented the pros and cons of 
both 18F-FDG PET-CT and conventional imaging. 18F-FDG 
PET-CT is able to perform a whole-body evaluation in one 
session [5]. This will shorten the time until start of treat-
ment and perhaps will reduce health care-related costs, due 
a to lower number of hospitals visits, additional diagnos-
tic procedures, and unnecessary curative treatments [13]. 
However, further studies are needed to investigate the cost-
effectiveness of 18F-FDG PET-CT, whether these possible 
lower costs would indeed outweigh the high costs of 18F-
FDG PET-CT. As was shown in this study, the percentage of 
patients with isolated IBTR screened with 18F-FDG PET-CT 
increased over the years, while the use of conventional imag-
ing decreased. Whether 18F-FDG PET-CT should replace 
conventional imaging in the preoperative staging of patients 
with IBTR should preferably depend on more aspects 
besides its diagnostic accuracy and cost-effectiveness, but 
also on the impact on prognosis and quality of life.
Some caveats apply to this study; because of its retrospec-
tive nature, reasons to use conventional imaging, 18F-FDG 
PET-CT, or no imaging for staging were not always reported 
in the patient files. All patients with IBTR and synchronous 
metastatic disease were not considered for inclusion and 
therefore not registered in the database. Data are lacking 
regarding the numbers of excluded patients and how these 
synchronous metastasis were detected. Further research is 
encouraged to evaluate the impact of the different imaging 
modalities on the prognosis and to determine factors asso-
ciated with an increased risk of synchronous metastases. 
Lastly, the diagnostic accuracy of 18F-FDG PET-CT and 
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conventional imaging modalities are likely to vary depend-
ing on the different techniques used between the different 
hospitals, regarding length of radioisotope uptake, image 
acquisition time, and the mode of image interpretation. 
Nonetheless, the current study is based on the largest cohort 
of patients with an IBTR, as far as we are aware of. Further-
more, this is a multicenter, nationwide study providing data 
of different types of hospitals in the Netherlands, representa-
tive for IBTR patients in daily practice.
Conclusions
This study showed a wide variation in the use of imaging 
modalities for staging of IBTR patients in the Netherlands. 
After propensity score weighting, no statistically significant 
impact of the different imaging modalities on the DRFI was 
shown. Based on these results, it is not possible to recom-
mend staging for distant metastases using 18F-FDG PET-CT 
over conventional imaging techniques.
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